A previous version of this story was published, in slightly different form, on Dec. 26, 2001. Expect to get to know Clarinex. Expect to associate the name with a theme song, a slogan, and--in all ...
Expect to know Clarinex. Expect to associate the name with a theme song, a slogan, and--in all likelihood--images of women or children running happily through flowering spring meadows. Expect ...
Sept. 7, 2004 -- The U.S. Food and Drug Administration (FDA) has approved an implantable metal rod for children with thoracic insufficiency syndrome, desloratadine for pediatric use, a heel-stick test ...
The FDA has given its consent for the novel version of the allergy medicine, Clarinex-D 12 Hour, to alleviate nasal, non nasal symptoms and nasal congestion occurring in adults and children above the ...
LARGO, Fla., Jan. 20, 2009 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that it has reached agreement with the Schering Corporation ("Schering"), and Sepracor, Inc ...
After nearly three years of fighting in the US District Court, New Jersey, Orchid Chemicals & Pharmaceuticals Ltd on Wednesday announced the settlement of patent litigation with US-based ...
PITTSBURGH (AP) -- Mylan has begun selling generic versions of the allergy drug Clarinex and also the bipolar disorder treatment Lithobid. The products starting shipping after approval was granted by ...
You may have seen those strange new television ads for Clarinex, Schering-Plough's chip-off-the-old-blockbuster replacement for its non-sedating antihistamine pill, Claritin. Crowds mill on a grassy ...
LOS ANGELES, Aug 11 (Reuters) - Drugmaker Schering-Plough Corp related to generic versions of its allergy medication, Clarinex. The agreement marks the end of all pending lawsuits filed and ...
A newer version of the prescription allergy medicine Clarinex has been approved by the FDA to treat nasal and non-nasal symptoms of seasonal allergies including nasal congestion in adults and children ...
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, falls early victim to generic competition. Early, as in next year. In court ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. © 2026 American City Business Journals. All rights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results